Celldex Therapeutics (CLDX) Insider Conrad Buys 26,000 Shares

Major Insider Buying at Celldex Therapeutics

Herbert Conrad acquired 26,000 shares of Celldex Therapeutics, Inc. (CLDX) on June 25, 2026. This transaction was part of a coordinated series of purchases by the company's top leadership. On the same day, several other high-ranking officials also boosted their holdings, signaling a collective commitment from those running the business. The company, which trades on the Nasdaq, focuses on developing complex antibodies to treat severe inflammatory and allergic diseases.

This flurry of activity included President and CEO Anthony Marucci, who bought 375,000 shares. Tibor Keler, the Executive VP and Chief Scientific Officer, added 115,000 shares, while Sarah Cavanaugh and Margo Heath-Chiozzi, both Senior VPs, each picked up 95,000 shares. Additionally, Freddy Jimenez, the General Counsel, bought 93,000 shares, and director Harry Penner Jr. matched Conrad with a 26,000-share purchase. None of these trades were part of a Rule 10b5-1 plan, which is a preset schedule insiders sometimes use to avoid conflict-of-interest concerns.

Celldex Stock Performance and Market Position

On Tuesday, Celldex shares were trading near $37.44. The stock has shown resilience over the past year, staying well clear of its 52-week low of $22.10. While the price is currently sitting a bit under its 50-day moving average of $39.10, it remains comfortably higher than its long-term 200-day average of $32.18. This suggests the stock has maintained a general upward trend over the last several months.

With a market valuation of roughly $2.98 billion, Celldex is a mid-sized player in the biotech space. The company's balance sheet looks stable for a development-stage firm, showing a current ratio of 11.82. This ratio measures a company's ability to pay its short-term debts, and a number this high indicates plenty of cash on hand to fund ongoing clinical trials.

Recent Financial Results

In its most recent financial updates, Celldex reported revenue of $158,000. Like many biotechnology companies focused on research and development, Celldex is not yet profitable, which is why it does not have a traditional P/E ratio. The company reported a net loss, resulting in an earnings per share (EPS) of -$4.35. Investors typically look past current losses in this sector, focusing instead on the progress of drug candidates like Barzolvolimab, which is being tested for chronic skin and lung conditions. The next earnings report is scheduled for November 9, 2026.

Analysts Set New Price Targets

Wall Street remains highly optimistic about Celldex's prospects. On October 2, 2026, H.C. Wainwright & Co. reiterated its Buy rating with a $64.00 price target. This followed a series of target hikes in late September. Leerink Partners maintained an Outperform rating on September 23 and boosted its target significantly to $88.00 from $70.00. On the same day, Morgan Stanley kept its Overweight rating and raised its target to $57.00.

Other firms are also aiming high. Cantor Fitzgerald has an Overweight rating with a $72.00 target, and Barclays set its target at $53.00 in August. Across 14 different analyst opinions, the stock holds a "strong buy" consensus. The average price target of $59.07 suggests that experts believe the stock has significant room to grow from its current levels.

Developing New Therapies

Celldex Therapeutics is a biopharmaceutical company based in Hampton, New Jersey. It spends its time and resources creating monoclonal and bispecific antibodies. These are essentially lab-made proteins designed to target specific parts of the immune system that cause chronic inflammation. Their lead program, Barzolvolimab, is being studied for its ability to block the KIT receptor, which plays a major role in various allergic and inflammatory responses. The heavy insider buying suggests the team is confident in the clinical data they are seeing as these programs move through testing.

Investors should keep an eye on the upcoming November earnings call for updates on clinical trial timelines. While the recent insider purchases are a positive sign of internal confidence, these SEC filings are backward-looking and only show what happened on the transaction date.